검 색
Interview
Articles
Industry
Info
기사 목록
Personalized Medicine: Talk is Cheap
The 2nd New York Health Forum
Featured Story of Korean Pharma: Hanwha confirms abandoning bid for Dow Chemical basic chemical units
Astellas/Medivation’s Xtandi has questionable potential to displace bicalutamide, other therapies in pre-chemotherapy mCRPC
Spark’s LCA2 gene therapy is likely to have greater benefit for younger patients
WKMO Global Leadership Series London Forum 2015
Chul Kyoon Park, President of it’s a Wig
INSPIRATIONAL KOREAN HEALTHCARE LEADER “Dr. Kwang Tae Kim, President of International Hospital Federation”
December 2014 - February 2015
Biosimilar Reference Products Expected to Grow
10
/ 15
10 / 15
